Company intelligence / Profile preview

Immuno-Biological Laboratories

Fujioka City, Chiba, Japan

Ownership: Private
Employees: ~51
Development stage: Other

Overview

IBL supplies high-quality antibodies and research assays—especially ELISA kits—used globally for cancer, neurodegenerative, infectious, and metabolic disease research. Their transgenic silkworm technology enables production of advanced proteins and human collagen for both medical diagnostics and cosmetics.

Therapeutic areas: ImmunologyEndocrinologyInfectious DiseasesNeurologyOncology
Modalities: AntibodyProteinEnzymeRecombinant proteinELISA kitsChemiluminescent diagnostic tools
Industry: Protein Biomarker Diagnostics

Partnerships

International diagnostic manufacturerspharmaceutical companies (licensees; names undisclosed)

Beyond the preview

Go deeper on Immuno-Biological Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immuno-Biological Laboratories.

Explore the full profile